Targeting the extracellular region of these receptors has been successful for the development of monoclonal antibodies with anti-tumor properties [10–13]; however, small molecule inhibitors targeting their intracellular regions have been described only for ROR1 [3], largely because their structural and functional properties are not fully characterized. Here, ROR1 is linked to neoplasm.